Expanding Ethical Standards of HMR: Necessary Evils and the Multiple Dimensions of Impact

Ethical challenges abound in HRM. Each day, in the course of executing and communicating HR decisions, managers have the potential to change, shape, redirect, and fundamentally alter the course of other people\u27s lives. Managers make hiring decisions that reward selected applicants with salaries, benefits, knowledge, and skills, but leave the remaining applicants bereft of these opportunities and advantages. Managers make promotion decisions that reward selected employees with raises, status, and responsibility, leaving other employees wondering about their future and their potential. Managers make firing and lay-off decisions in order to improve corporate performance, all the while harming the targeted individuals and even undermining the commitment and energy of survivors. Even when managers complete performance appraisals and deliver performance feedback, they may inspire one employee and devastate another. For each HR practice, there are winners and there are losers: Those who get the job, or receive a portfolio of benefits, and those who do not

A trip down memory lane with Retrovirology

Fifteen years ago, Retrovirology was amongst the first open-access journals to be established through Biomed Central, instigated by our late Founding Editor Dr. Kuan-Teh Jeang. Since then, in what seemed like a rather daring move to be paper-free, Retrovirology has witnessed the exponential growth of open access journals that have changed the landscape of scientific publishing and communications. As was pointed out by the staff editors in PLoS Biology [1], the infancy of open access journal was a very different time from our present day, which was before smartphones, prior to most of the digital social media platforms and at a time when we had only begun to learn about the completed DNA sequences from the Human Genome Projec

Effect of a Brief Video Intervention on Incident Infection among Patients Attending Sexually Transmitted Disease Clinics

In a controlled trial at three urban STD clinics, Lee Warner and colleagues find that showing an educational video in waiting rooms reduced new infections by approximately 10%

Global parameterization and validation of a two-leaf light use efficiency model for predicting gross primary production across FLUXNET sites:TL-LUE Parameterization and Validation

Light use efficiency (LUE) models are widely used to simulate gross primary production (GPP). However, the treatment of the plant canopy as a big leaf by these models can introduce large uncertainties in simulated GPP. Recently, a two-leaf light use efficiency (TL-LUE) model was developed to simulate GPP separately for sunlit and shaded leaves and has been shown to outperform the big-leaf MOD17 model at six FLUX sites in China. In this study we investigated the performance of the TL-LUE model for a wider range of biomes. For this we optimized the parameters and tested the TL-LUE model using data from 98 FLUXNET sites which are distributed across the globe. The results showed that the TL-LUE model performed in general better than the MOD17 model in simulating 8 day GPP. Optimized maximum light use efficiency of shaded leaves (εmsh) was 2.63 to 4.59 times that of sunlit leaves (εmsu). Generally, the relationships of εmsh and εmsu with εmax were well described by linear equations, indicating the existence of general patterns across biomes. GPP simulated by the TL-LUE model was much less sensitive to biases in the photosynthetically active radiation (PAR) input than the MOD17 model. The results of this study suggest that the proposed TL-LUE model has the potential for simulating regional and global GPP of terrestrial ecosystems, and it is more robust with regard to usual biases in input data than existing approaches which neglect the bimodal within-canopy distribution of PAR

Data-driven diagnostics of terrestrial carbon dynamics over North America

The exchange of carbon dioxide is a key measure of ecosystem metabolism and a critical intersection between the terrestrial biosphere and the Earth’s climate. Despite the general agreement that the terrestrial ecosystems in North America provide a sizeable carbon sink, the size and distribution of the sink remain uncertain. We use a data-driven approach to upscale eddy covariance flux observations from towers to the continental scale by integrating flux observations, meteorology, stand age, aboveground biomass, and a proxy for canopy nitrogen concentrations from AmeriFlux and Fluxnet-Canada Research Network as well as a variety of satellite data streams from the MODIS sensors. We then use the resulting gridded flux estimates from March 2000 to December 2012 to assess the magnitude, distribution, and interannual variability of carbon fluxes for the U.S. and Canada. The mean annual gross primary productivity (GPP), ecosystem respiration (ER), and net ecosystem productivity (NEP) of the U.S. over the period 2001–2012 were 6.84, 5.31, and 1.10 Pg C yr⁻¹, respectively; the mean annual GPP, ER, and NEP of Canada over the same 12-year period were 3.91, 3.26, and 0.60 Pg C yr⁻¹, respectively. The mean nationwide annual NEP of natural ecosystems over the period 2001–2012 was 0.53 Pg C yr⁻¹ for the U.S. and 0.49 Pg C yr⁻¹ for the conterminous U.S. Our estimate of the carbon sink for the conterminous U.S. was almost identical with the estimate of the First State of the Carbon Cycle Report (SOCCR). The carbon fluxes exhibited relatively large interannual variability over the study period. The main sources of the interannual variability in carbon fluxes included drought and disturbance. The annual GPP and NEP were strongly related to annual evapotranspiration (ET) for both the U.S. and Canada, showing that the carbon and water cycles were closely coupled. Our gridded flux estimates provided an independent, alternative perspective on ecosystem carbon exchange over North America.KEYWORDS: Eddy covariance, Drought, Carbon sink, Carbon source, Disturbance, EVIThis is the publisher’s final pdf. The published article is copyrighted by Elsevier and can be found at: http://www.journals.elsevier.com/agricultural-and-forest-meteorolog

Age and Disability Employment Discrimination: Occupational Rehabilitation Implications

Introduction As concerns grow that a thinning labor force due to retirement will lead to worker shortages, it becomes critical to support positive employment outcomes of groups who have been underutilized, specifically older workers and workers with disabilities. Better understanding perceived age and disability discrimination and their intersection can help rehabilitation specialists and employers address challenges expected as a result of the evolving workforce. Methods Using U.S. Equal Employment Opportunity Commission Integrated Mission System data, we investigate the nature of employment discrimination charges that cite the Americans with Disabilities Act or Age Discrimination in Employment Act individually or jointly. We focus on trends in joint filings over time and across categories of age, types of disabilities, and alleged discriminatory behavior. Results We find that employment discrimination claims that originate from older or disabled workers are concentrated within a subset of issues that include reasonable accommodation, retaliation, and termination. Age-related disabilities are more frequently referenced in joint cases than in the overall pool of ADA filings, while the psychiatric disorders are less often referenced in joint cases. When examining charges made by those protected under both the ADA and ADEA, results from a logit model indicate that in comparison to charges filed under the ADA alone, jointly-filed ADA/ADEA charges are more likely to be filed by older individuals, by those who perceive discrimination in hiring and termination, and to originate from within the smallest firms. Conclusion In light of these findings, rehabilitation and workplace practices to maximize the hiring and retention of older workers and those with disabilities are discussed

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19. METHODS: In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978. FINDINGS: Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50-72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74-1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67-1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74-1·58]; BRII-196 plus BRII-198 1·00 [0·68-1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91-1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88-1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90. INTERPRETATION: Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19. FUNDING: US National Institutes of Health and Operation Warp Speed

Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated

Many HIV-1 envelope-reactive antibodies shortly after HIV-1 transmission may arise from crow-reactive memory B cells previously stimulated by non-HIV-1 host or microbial antigen

Cell Cycle Phase Regulates Glucocorticoid Receptor Function

The glucocorticoid receptor (GR) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors. In contrast to many other nuclear receptors, GR is thought to be exclusively cytoplasmic in quiescent cells, and only translocate to the nucleus on ligand binding. We now demonstrate significant nuclear GR in the absence of ligand, which requires nuclear localisation signal 1 (NLS1). Live cell imaging reveals dramatic GR import into the nucleus through interphase and rapid exclusion of the GR from the nucleus at the onset of mitosis, which persists into early G1. This suggests that the heterogeneity in GR distribution is reflective of cell cycle phase